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The efficacy of antibiotic treatments in dairy cows at dry-off to prevent new
intramammary infections during the dry-period or clinical mastitis during
early lactation: A protocol for a systematic review
Abstract
Rationale: The majority of antibiotic use in the dairy industry is for the treatment and prevention of
intramammary infections (IMI); in the Netherlands, approximately 60 % of all antimicrobial use in dairy is for
this purpose, with two-thirds being dry cow therapy (Lam et al., 2012). In the United States, over 90 % of
dairy cows receive dry cow therapy after every lactation (USDA-APHIS, 2016), with the goal of treating or
preventing IMI during the dry period. These infections are strongly associated with risk of development of
clinical mastitis in the first two weeks post-calving, which represents the highest risk period for this disease
(Green et al., 2002). To combat this, blanket dry cow therapy (intramammary antimicrobial treatment of all
quarters of all cows after the last milking of the lactation) was recommended for decades as part of a
comprehensive strategy to reduce IMI in the dry period (Neave et al., 1969), and has been widely adopted in
North America and the United Kingdom (Ruegg, 2017). Although cow2 level selective dry cow therapy has
been in use in some regions for several decades (Schultze, 1983), interest has more recently increased
worldwide, in part driven by concern for antimicrobial use and its relationship with the development of
antimicrobial resistance between species (WHO, 2015), including nation-specific regulations (Santman-
Berends et al., 2016). Selective dry cow therapy has been employed because it is a means to rapidly reduce the
amount of antimicrobials used in dairy cattle (Vanhoudt et al., 2018), rather than because it is known to
contribute importantly to antimicrobial resistance (Oliver et al., 2011).
With a greater concern for prudent antibiotic use in the dairy industry, it is important that decision making
with regards to dry cow therapy at both the cow and herd levels be evidencebased. Choosing ineffective
antibiotics, or using antibiotic when not warranted, unnecessarily contributes to use while having little impact
on controlling disease, which has substantial bearing to both profitability and animal welfare (Leslie &
Petersson-Wolfe, 2012). Systematic reviews of randomized controlled trials yield the highest level of evidence
for efficacy of treatment under field conditions (Sargeant and O’Connor, 2014), and comparative efficacy can
be examined using network meta-analysis for multiple comparisons. Establishing the efficacy of both cow-
level antibiotic therapy and herd-level dry cow antibiotic protocols for the prevention of IMI will serve to
improve decision makers’ ability to engage in effective stewardship of antibiotics.
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The FDA website containing the Freedom of Information New Animal Drug Approvals (NADA) 



























"cloxacillin"	 OR	 "CTC"	 OR	 "danofloxacin"	 OR	 "dicloxacillin"	 OR	 "dihydrostreptomycin"	 OR	
"enrofloxacin"	 OR	 "erythromycin"	 OR	 "florfenicol"	 OR	 "framycetin"	 OR	 "gamithromycin"	 OR	
"gentamicin"	 OR	 "gentamycin"	 OR	 "lincomycin"	 OR	 lincosamide*	 OR	 "neomycin"	 OR	
"novobiocin"	 OR	 "oxytetracycline"	 OR	 "penethamate"	 OR	 "penicillin"	 OR	 "pirlimycin"	 OR	
"piroline"	 OR	 "spectinomycin"	 OR	 "sulfadimethoxine"	 OR	 "sulfafurazole"	 OR	
"sulfamethoxazole"	 OR	 "sulfisoxazole"	 OR	 "sulphadimethoxine"	 OR	 "tetracycline"	 OR	
"tildipirosin"	 OR	 "tilmicosin"	 OR	 "trimethoprim"	 OR	 "tulathromycin"	 OR	 "tylosin")
	 147,813	
#	9	 TS=(antimicrobial*	 OR	 "anti-microbial*"	 OR	 antibiotic*	 OR	 "anti-biotic*"	 OR	








OR	 "drying	 period*"	OR	 "dry	 period*"	OR	 "dry	 udder*"	OR	 "dry	 teat*"	OR	 "pre-partum"	OR	
"prepartum"	OR	(("end"	OR	finish*	OR	stop*	OR	ceas*)	NEAR/3	lactat*)	OR	nonlactat*	OR	"non-





holstein*	 OR	 illawarra*	 OR	 "irish	 moiled*"	 OR	 jersey*	 OR	 "meuse	 rhine	 issel*"	 OR	
































































o Antibiotic(s)	 used,	 route	 of	 administration,	 frequency	 of	 administration,	 dose,	
any	concurrent	treatments,		





The	 above	 data	 will	 be	 collect	 for	 all	 of	 the	 primary	 hypothesis-testing	 studies	 that	 are	










• Any	 additional	 concurrent	 treatments	 –	 studies	 with	 additional	 treatments	 will	 be	
considered	 as	 separate	 treatments	 arms	 to	 studies	 with	 only	 an	 antibiotic-containing	
dry	cow	product.	
	
Outcomes	and	prioritization:			
	
Critical	outcomes	(in	order	of	prioritization):	
- Incidence	of	clinical	mastitis	during	the	first	30	days	of	the	subsequent	lactation	
- Reduction	in	new	IMI	during	the	dry-cow	period	(individual	level)	or	new	and	existing	
IMI	during	the	dry-cow	period	(group	level).	
- Reduction	of	new	IMI	during	the	first	30	days	of	lactation	(individual	level)	or	new	and	
existing	IMI	during	the	dry-cow	period	(group	level).	
			
Secondary	outcomes	(in	order	of	prioritization):	
- Total	antibiotic	use	to	treat	clinical	mastitis	during	the	first	30	days	of	the	subsequent	
lactation.	
- Milk	production	during	the	subsequent	lactation	
- Somatic	cell	count	the	first	test	of	the	subsequent	lactation,	or	the	average	of	the	first	3	
tests	of	the	subsequent	lactation.		
- Risk	of	culling	due	to	mastitis	during	the	subsequent	lactation.	
These	outcomes	were	prioritized	based	on	their	impact	on	animal	health	and	welfare	and	their	
economic	importance.		Formal	evaluation	of	these	criteria	for	prioritization	was	not	
undertaken.	
	
Data	will	be	collected	to	describe	the	outcomes	that	were	evaluated	for	all	eligible	studies,	
regardless	of	study	design.		The	specific	outcome	data,	as	described	below,	will	be	extracted	
only	for	experimental	studies	with	natural	disease	exposure.	
	
Outcome	data	to	be	collected:	
1) Incidence	of	clinical	mastitis	during	the	subsequent	lactation	
a. Case	definition	of	clinical	mastitis	
b. Level	at	which	outcome	data	were	measured	(quarter,	composite	individual,	
group)	
	
2) Outcomes	related	to	IMI	
a. Method	of	determining	the	study	subjects	were	free	of	IMI	at	dry-off	(individual	
level	review	question):	
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i. Negative	culture	at	dry	off	(extract	data	on	quarter	or	composite)	
ii. Somatic	cell	count	below	a	threshold	(extract	data	on	threshold	and	time	
period	for	assessment)	
iii. No	clinical	case	of	mastitis	during	specified	duration	(extract	data	on	
duration)	
iv. Other	(specify)	
v. Not	assessed	–	excluded	from	meta-analysis,	as	cannot	distinguish	
incident	from	prevalent	cases.		
b. Level	at	which	the	outcomes	were	measured	(quarter,	composite	individual,	
group)	
c. Method	of	diagnosis	of	IMI	status:	
i. Number	of	milk	samples	used	to	classify	IMI	status	and	timing	of	
sampling	for	cultures		
ii. Whether	National	Mastitis	Council	(NMC)	Laboratory	Methods	were	
stated	as	used			
iii. If	other	methods	were	used	in	parallel	or	exclusively	e.g.	PCR;	Petrifilm	or	
selective	media	
d. Type	of	bacteria:	
i. Individual	bacteria	results	will	be	extracted	for:	Coliforms,	Strep.	uberis,	
Strep.	agalactica,	Staph.	aureus	
ii. Grouped	bacteria	results	will	be	extracted	for:	Major	contagious	mastitis	
pathogens	(Staph.	aureus	and	Strep.	agalactia),	and	Major	environmental	
mastitis	pathogens	(Strep.	uberis	and	coliforms)	
	
For	each	of	the	primary	and	secondary	outcomes,	we	will	extract	the	possible	metrics	in	the	
following	order:		
• 1st	priority:	Adjusted	summary	effect	size	(adjusted	risk	ratio	or	adjusted	odds	ratio,	mean	
differences	for	continuous	outcomes)	and	variables	included	in	adjustment	and	
corresponding	precision	estimate.		
• 2nd	priority:	Unadjusted	summary	effect	size				
• 3rd	priority:	Arm	level	risk	of	the	outcome,	or	arm	level	mean	of	the	outcome	
(continuous	outcomes)	
• For	cluster-randomized	designs,	the	approach	to	the	analysis	of	non-independent	
observations	i.e.,	not	reported,	‘multilevel	model,'	a	‘variance	components	analysis'	or	
may	use	‘generalized	estimating	equations	(GEEs),'	among	other	techniques.			
• Variance	components	
	
If	variance	estimates	are	not	reported,	but	the	authors	provide	the	data	necessary	to	calculate	
them	using	standard	formulas,	we	will	calculate	these	data.		If	results	are	provided	only	in	
graphical	form,	we	will	estimate	the	numerical	results	using	WebPlotDigitizer	
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(https://automeris.io/WebPlotDigitizer/),	if	the	full	text	is	in	a	suitable	format	for	using	this	
resource.	
	
Risk	of	bias	in	individual	studies:		Risk	of	bias	will	only	be	assessed	for	controlled	trials	with	
natural	disease	exposure.		Risk	of	bias	assessment	will	be	performed	at	the	outcome	level	for	
each	of	the	critical	outcomes	using	the	Cochrane	risk	of	bias	instrument	(Higgins	et	all,	2016),	
with	the	signaling	questions	modified	as	necessary	for	the	specific	review	question.	The	ROB-
2.0	for	clustered	–RCT	and	individual	RCTs	will	be	used	depending	upon	the	study	design.		
These	tools	are	available	at	https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool.	
	
Data	synthesis:		
	
Network	meta-analysis.	Network	meta-analysis	(aka	mixed	treatment	comparison	meta-
analysis)	will	be	conducted	for	each	of	the	primary	outcomes	and	separately	for	the	individual	
level	and	group	level	questions,	as	the	group	level	question	by	necessity	combines	incident	and	
prevalent	IMI.		Network	meta-analysis	will	use	the	approach	described	by	NICE	Decision	
Support	Unit	technical	document	(Dias	et	al.,	2014;	O’Connor	et	al.,	2013,	O’Connor	et	al.,	
2016).	The	approach	to	reporting	will	use	the	PRISMA-	NMA	(http://www.prisma-
statement.org/Extensions/NetworkMetaAnalysis.aspx).		Planned	a	priori	sub-group	analyses	
will	be	conducted	for	randomized	versus	non-randomized	trials	and,	for	the	group	level	review	
question,	by	method	of	selecting	the	cows	for	treatment.	
	
Meta-bias(es):		Small	study	effects	(“publication	bias”)	will	be	assessed	for	all	antibiotic-
comparator	combinations	where	there	are	at	least	10	studies	in	the	meta-analysis.	If	feasible,	
we	will	use	approaches	to	assessing	publication	bias	in	the	network	of	evidence	using	
previously	proposed	approaches	(Mavridis	et	al.,	2013;	Mavridis	et	al.,	2014).		
Confidence	 in	cumulative	evidence:	 	The	quality	of	evidence	for	each	critical	outcome	will	be	
assessed	using	the	approach	proposed	by	GRADE	(GRADE,	2015,	Puhan	et	al.,	2014),	while	also	
considering	the	nature	of	the	network	meta-analysis	(Jansen	et	al.,	2011).	
Discussion:		
	
This	systematic	review	will	provide	a	synthesis	of	the	current	evidence	regarding	the	efficacy	of	
antibiotic-containing	dry	cow	treatments	at	the	individual	level	for	preventing	mastitis	and	
treatment	strategies	at	the	group	level	for	preventing	and	treating	mastitis	during	the	dry	cow	
period	and	early	lactation.		Results	will	be	helpful	for	veterinarians	and	dairy	producers	when	
making	evidence-informed	decisions	regarding	the	use	of	antibiotic-containing	dry	cow	
treatment.		The	results	also	will	be	helpful	for	identifying	specific	gaps	in	knowledge	related	to	
the	efficacy	of	these	products	for	targeting	additional	research.	
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